🚀 RECENT AI SUCCESS

Our AI successfully predicted the gap for $SFIX and executed a BUY strategy, securing a +31.52% net profit.

UPGRADE TO SEE LIVE SIGNALS

$ALT

Altimmune Inc

United StatesUNITED STATES
FREE PREVIEW
📅 Next Earnings: Aug 11, 2026 ☀️ Open🌐 Website🏛️ NASDAQ📁 Health Technology🏭 Biotechnology
AVG HISTORICAL GAP1.83%
MAX GAP RECORD7.75%
PREMIUM
AI ACCURACY RATE
92.4%
Unlock AI Insights 🔓

LAST 10 EARNINGS GAPS (%)

VOLATILITY & BIAS PROFILE

AVG VOLATILITY2.9%
Bullish Gaps
Bearish Gaps
Neutral

Intelligence Brief

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a… Read full dossier

CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL

AI INSIGHTS & REPORTS FOR ALT

AI REPORT Jun 10

Daily Champions: Identifying Top Stocks with High Confidence

AnalysisWhile global markets have shown recent volatility, particularly driven by concerns over $AI developments in China and broader…
VIEW REPORT_
AI REPORT Jun 04

The Shift in Sector Rotation: Where Institutional Money is Flowing

Analysis Markets are currently experiencing a significant shift in sector rotation, driven by macroeconomic factors and earnings reports.…
VIEW REPORT_
AI REPORT Jun 04

RCO.PA: A Deep Dive into Earnings Gap Anticipation

Analysis Markets are buzzing with anticipation as $RCO.PA, a key player in the technology sector, prepares to release…
VIEW REPORT_